@article{2485f39eb62e4fc1b587a39aeea02908,
title = "Maternal stress and depression are associated with respiratory phenotypes in urban children",
abstract = "Background: Prenatal and early-life exposure to maternal stress and depression is linked to development of recurrent wheezing in young children. Objective: We sought to determine whether maternal stress and depression in early life are associated with nonatopic wheezing phenotype in urban children. Methods: The Urban Environment and Childhood Asthma Study examined a birth cohort of children at high risk for asthma in low-income neighborhoods. Prenatal and postnatal (through age 3 years) maternal stress and depression scores were compared with respiratory phenotypes through age 10 years (multinomial regression), self-reported colds (linear regression), and detection of respiratory viruses (Poisson regression). Results: Scores for maternal depression, and, to a lesser extent, maternal perceived stress, were positively related to multiple wheezing phenotypes. In particular, cumulative measures of maternal depression in the first 3 years were related to the moderate-wheeze-low-atopy phenotype (odds ratio, 1.13; [1.05, 1.21]; P < .01). Considering indicators of respiratory health that were used to identify the phenotypes, there were multiple positive associations between early-life scores for maternal stress and depression and increased wheezing illnesses, but no consistent relationships with lung function and some inverse relationships with allergic sensitization. Cumulative maternal stress and depression scores were associated with cumulative number of respiratory illnesses through age 3 years. Conclusions: Among high-risk, urban children, maternal stress and depression in early life were positively associated with respiratory illnesses and a moderate-wheeze-low-atopy phenotype. These results suggest that treating stress and depression in expectant and new mothers could reduce viral respiratory illnesses and recurrent wheeze during the preschool years and some forms of childhood asthma.",
keywords = "Asthma, allergic sensitization, atopy, maternal depression, pediatrics, wheeze",
author = "{Inner City Asthma Consortium} and Ramratnam, {Sima K.} and Alexandre Lockhart and Visness, {Cynthia M.} and Agustin Calatroni and Jackson, {Daniel J.} and Gergen, {Peter J.} and Bacharier, {Leonard B.} and O'Connor, {George T.} and Sandel, {Megan T.} and Meyer Kattan and Wood, {Robert A.} and Gern, {James E.}",
note = "Funding Information: Disclosure of potential conflict of interest: All authors with the exception of P. J. Gergen report grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/Division of Allergy, Immunology, and Transplantation (DAIT) during the conduct of study. D. J. Jackson reports grants from GlaxoSmithKline and NIH/National Heart, Lung, and Blood Institute (NHLBI), as well as personal fees from Novartis, Commense, Sanofi/Genzyme, Boehringer Ingelheim, and Pfizer outside the submitted work. L. B. Bacharier reports grant support from NIH/NIAID/NHLBI, Sanofi, and Vectura, and personal fees from GlaxoSmithKline, Genentech, Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Regeneron, Vectura, and Circassia outside the submitted work. M. Kattan reports personal fees from Novartis and Regeneron for service on advisory boards outside the submitted work. R. A. Wood reports board membership at the American Academy of Allergy, Asthma, and Immunology, employment at Johns Hopkins University, royalties from UpToDate outside the submitted work, and grants from NIH, DBV Technologies, Aimmune Therapeutics, Astellas Pharma, and HAL Allergy Group outside the submitted work. J. E. Gern reports consulting fees from Regeneron, consulting fees and stock options from Meissa Vaccines, Inc, and consulting fees from AstraZeneca outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health , under the following contract numbers: NO1-AI-25496, NO1-AI-254821, HHSN272200900052C, HHSN272201000052I, UM1AI114271-01 , and UM2AI117870 . Additional support was provided by the National Center for Research Resources, National Institutes of Health , under the following grant numbers: RR00052, UL1TR001079, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, UL1TR000040 , and 5UL1RR024992-02 . Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under the following contract numbers: NO1-AI-25496, NO1-AI-254821, HHSN272200900052C, HHSN272201000052I, UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources, National Institutes of Health, under the following grant numbers: RR00052, UL1TR001079, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, UL1TR000040, and 5UL1RR024992-02. Disclosure of potential conflict of interest: All authors with the exception of P. J. Gergen report grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/Division of Allergy, Immunology, and Transplantation (DAIT) during the conduct of study. D. J. Jackson reports grants from GlaxoSmithKline and NIH/National Heart, Lung, and Blood Institute (NHLBI), as well as personal fees from Novartis, Commense, Sanofi/Genzyme, Boehringer Ingelheim, and Pfizer outside the submitted work. L. B. Bacharier reports grant support from NIH/NIAID/NHLBI, Sanofi, and Vectura, and personal fees from GlaxoSmithKline, Genentech, Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Regeneron, Vectura, and Circassia outside the submitted work. M. Kattan reports personal fees from Novartis and Regeneron for service on advisory boards outside the submitted work. R. A. Wood reports board membership at the American Academy of Allergy, Asthma, and Immunology, employment at Johns Hopkins University, royalties from UpToDate outside the submitted work, and grants from NIH, DBV Technologies, Aimmune Therapeutics, Astellas Pharma, and HAL Allergy Group outside the submitted work. J. E. Gern reports consulting fees from Regeneron, consulting fees and stock options from Meissa Vaccines, Inc, and consulting fees from AstraZeneca outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: {\textcopyright} 2021 American Academy of Allergy, Asthma & Immunology",
year = "2021",
month = jul,
doi = "10.1016/j.jaci.2021.03.005",
language = "English (US)",
volume = "148",
pages = "120--127",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",
}